Volume | 45,316 |
|
|||||
News | - | ||||||
Day High | 2.81 | Low High |
|||||
Day Low | 2.55 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
First Wave BioPharma Inc | FWBI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
2.67 | 2.55 | 2.81 | 2.74 | 2.73 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
278 | 45,316 | US$ 2.68 | US$ 121,228 | - | 2.42 - 64.998 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
16:37:54 | formt | 200 | US$ 2.82 | USD |
First Wave BioPharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.85M | 675.00k | - | 0 | -16.1M | -23.86 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
First Wave BioPharma News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FWBI Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.02 | 3.3999 | 2.42 | 2.92 | 82,234 | -0.20 | -6.62% |
1 Month | 4.58 | 4.58 | 2.42 | 3.25 | 48,142 | -1.76 | -38.43% |
3 Months | 5.20 | 9.35 | 2.42 | 5.55 | 94,640 | -2.38 | -45.77% |
6 Months | 5.60 | 14.51 | 2.42 | 5.38 | 476,633 | -2.78 | -49.64% |
1 Year | 56.80 | 64.998 | 2.42 | 14.46 | 1,594,256 | -53.98 | -95.04% |
3 Years | 483.00 | 686.00 | 2.42 | 98.22 | 1,444,307 | -480.18 | -99.42% |
5 Years | 483.00 | 686.00 | 2.42 | 98.22 | 1,444,307 | -480.18 | -99.42% |
First Wave BioPharma Description
First Wave BioPharma Inc is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. |